OBJECTIVE: Generalized anxiety disorder (GAD) is common, chronic, and debilitating. Treatment with benzodiazepines and newer antidepressants is often inadequate. This article reviews the effectiveness of alternative and augmenting medications, such as older antidepressants, antipsychotics, anticonvulsants, and β-blockers. DATA SOURCES: A search using MEDLINE (1980 to week 4 of May 2010) with the key words generalized anxiety disorder or GAD and therapeutics or treatment was conducted. Articles included adult patients with a GAD diagnosis that established chronicity of illness. These included a small number of studies that used DSM-III criteria but added a chronicity of symptoms and included all studies that used DSM-III-R and DSM-IV criteria. Articles that did not include medications or that exclusively focused on newer antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, and mirtazapine), buspirone, benzodiazepines, or herbal or investigational medications were excluded. Review articles and non-English-language articles were also excluded. RESULTS: Thirty-six studies were reviewed. All of the references were then analyzed, and key portions were extracted. Many studies were open trials. Double-blind, placebo-controlled studies with imipramine, risperidone, olanzapine, hydroxyzine, ondansetron, tiagabine, valproate, and pregabalin had been conducted. Imipramine, hydroxyzine, valproate, and pregabalin were the most effective, although risperidone, olanzapine, ziprasidone, and aripiprazole may also reduce symptoms. CONCLUSIONS: Several medication strategies can be considered as promising alternatives or augmenting to antidepressant or benzodiazepine therapy in GAD.
OBJECTIVE: Generalized anxiety disorder (GAD) is common, chronic, and debilitating. Treatment with benzodiazepines and newer antidepressants is often inadequate. This article reviews the effectiveness of alternative and augmenting medications, such as older antidepressants, antipsychotics, anticonvulsants, and β-blockers. DATA SOURCES: A search using MEDLINE (1980 to week 4 of May 2010) with the key words generalized anxiety disorder or GAD and therapeutics or treatment was conducted. Articles included adult patients with a GAD diagnosis that established chronicity of illness. These included a small number of studies that used DSM-III criteria but added a chronicity of symptoms and included all studies that used DSM-III-R and DSM-IV criteria. Articles that did not include medications or that exclusively focused on newer antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, and mirtazapine), buspirone, benzodiazepines, or herbal or investigational medications were excluded. Review articles and non-English-language articles were also excluded. RESULTS: Thirty-six studies were reviewed. All of the references were then analyzed, and key portions were extracted. Many studies were open trials. Double-blind, placebo-controlled studies with imipramine, risperidone, olanzapine, hydroxyzine, ondansetron, tiagabine, valproate, and pregabalin had been conducted. Imipramine, hydroxyzine, valproate, and pregabalin were the most effective, although risperidone, olanzapine, ziprasidone, and aripiprazole may also reduce symptoms. CONCLUSIONS: Several medication strategies can be considered as promising alternatives or augmenting to antidepressant or benzodiazepine therapy in GAD.
Authors: Thomas L Schwartz; Nouman Azhar; Juhi Husain; Nikhil Nihalani; Mihai Simionescu; Douglas Coovert; Shefali Jindal; Syed Tirmazi Journal: Ann Clin Psychiatry Date: 2005 Jul-Sep Impact factor: 1.567
Authors: Naomi M Simon; Elizabeth A Hoge; Diana Fischmann; John J Worthington; Kelly M Christian; Gustavo Kinrys; Mark H Pollack Journal: J Clin Psychiatry Date: 2006-03 Impact factor: 4.384
Authors: Elizabeth A Hoge; John J Worthington; Rebecca E Kaufman; Hannah R Delong; Mark H Pollack; Naomi M Simon Journal: CNS Spectr Date: 2008-06 Impact factor: 3.790
Authors: Borwin Bandelow; Guy Chouinard; Julio Bobes; Antti Ahokas; Ivan Eggens; Sherry Liu; Hans Eriksson Journal: Int J Neuropsychopharmacol Date: 2009-08-20 Impact factor: 5.176
Authors: Naomi M Simon; Kathryn M Connor; Richard T LeBeau; Elizabeth A Hoge; John J Worthington; Wei Zhang; Jonathan R T Davidson; Mark H Pollack Journal: Psychopharmacology (Berl) Date: 2008-02-02 Impact factor: 4.530
Authors: June Bryan I de la Peña; Hye Lim Lee; Seo Young Yoon; Gun Hee Kim; Yong Soo Lee; Jae Hoon Cheong Journal: J Nat Med Date: 2013-03-03 Impact factor: 2.343
Authors: Anna M Rosenhauer; Linda Q Beach; Elizabeth C Jeffress; Brittany M Thompson; Katharine E McCann; Katherine A Partrick; Bryan Diaz; Alisa Norvelle; Dennis C Choi; Kim L Huhman Journal: Neuropharmacology Date: 2018-12-14 Impact factor: 5.250
Authors: Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom Journal: Depress Anxiety Date: 2019-06-23 Impact factor: 6.505